Michael Baran, MBA, PHD is Executive Director, WRDM and Partner at Pfizer Ventures. Mike is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Anjarium Biosciences, Autobahn Therapeutics, Interius BioTherapeutics, ImCheck Therapeutics, ImmunOs Therapeutics, Magnolia Neurosciences, Mediar Therapeutics, Parthenon Therapeutics, and TRex Bio. His prior investment responsibilities include Accelerator Life Science Partners, Bluelight Therapeutics, AnTolRx, and Netvation DL. Mike is an Adjunct Assistant Professor in the Department of Biomedical Engineering at Stony Brook University and plays an active role in the NY/NJ early life science ecosystem as a Mentor in Residence for Rutgers University and a Venture Advisor for eLabNYC.s.